Fig. 2.

Nobiletin attenuates body weight, adiposity, and plasma lipids and enhances energy expenditure in both HFHC diet-fed Ampkβ1^−/− and WT mice. WT and Ampkβ1^−/− mice were fed a HFHC diet (HF) alone or HFHC plus nobiletin (+Nob) for 18 weeks, n = 5–6 per group. A: Immunoblot of pAMPK, AMPK, pACC, and ACC in liver lysates from WT and Ampkβ1^−/− mice fed a HFHC diet (HF) or a HFHC diet + nobiletin (N). Lysates were run on the same immunoblot. The slower running band (arrow) in the pAMPK blot in the Ampkβ1^−/− liver sample is nonspecific. B: Body weight measured weekly. * or # indicates a statistical difference from nobiletin-treated mice within the same genotype, determined by two-way ANOVA with repeated measures analyses, P < 0.05. C: Mean daily caloric intake measured weekly. D: Adiposity assessed as epididymal fat pad weight/total body weight. E: ANCOVA-adjusted mean energy expenditure (kilocalories per hour) over 24 h. F: RER over 24 h. G: Mean ambulatory activity (breaks/hour) over 24 h. H: Plasma cholesterol concentrations. I: Plasma TG concentrations. J: Plasma cholesterol FPLC tracing. K: Plasma LDL-C AUC calculations. L: Plasma HDL-C AUC calculations. Data represent the mean ± SEM. Different letters indicate statistical differences by ANOVA with post hoc Tukey’s test (P < 0.05). N.S., no significant difference.